Showing 121 - 140 results of 25,536 for search '(( 50 ng decrease ) OR ((( 50 ((ng decrease) OR (a decrease)) ) OR ( a point decrease ))))', query time: 0.52s Refine Results
  1. 121
  2. 122

    Behavior of split<sup><50cM</sup> <i>ClvR</i> V2 with linkage. by Georg Oberhofer (3401438)

    Published 2021
    “…<p>Incorporating linkage into split <i>ClvR</i> (split<sup><50cM</sup> <i>ClvR</i> V2) results in a graded increase in drive strength, and duration of <i>Rescue</i>/Cargo/gRNAs at high frequency, as the degree of linkage increases (map distance decreases). …”
  3. 123
  4. 124
  5. 125

    AMPs are increased in lesional HS, but DCD and other sweat-gland associated proteins are decreased. by Margaret Coates (6058580)

    Published 2019
    “…<p>(A) Volcano plot showing increased or decreased genes in HS. …”
  6. 126
  7. 127
  8. 128

    Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

    Published 2025
    “…<p>(A) Ki-67 expression in parathyroid glands of rats with CKD-induced sHPT treated with Cinacalcet either early in the inactive light phase (<i>Cina1</i>; N = 10) or early in the active dark phase (<i>Cina2</i>; N = 9) compared to untreated rats with sHPT investigated at similar time points (<i>PNX1</i>; N = 7 and <i>PNX2</i>; N = 7, respective) and to normal rats investigated at similar time points (<i>ctrl1</i>; N = 9 and <i>ctrl2</i>; N = 7, respective). …”
  9. 129
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134
  15. 135

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  16. 136

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  17. 137
  18. 138
  19. 139
  20. 140